Get started
Author

Brandy Menges

Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients
2017 · Steven Deitelzweig, Xuemei Luo, et al. · Current Medical Research and Opinion · 64
PDF
Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States
2018 · Jashin J. Wu, Steven R. Feldman, et al. · Journal of Dermatological Treatment · 45
Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA
2019 · Alpesh Amin, W Richey Neuman, et al. · Drugs in Context · 30
PDF
Economic Burden of Treatment-Resistant Depression Among Patients Hospitalized for Major Depressive Disorder in the United States
2019 · Jay Lin, Holly Szukis, et al. · Psychiatric Research and Clinical Practice · 28
PDF
Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors
2017 · Steven Deitelzweig, W. Richey Neuman, et al. · Journal of Medical Economics · 28
PDF
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting
2017 · Jay Lin, Jeffrey Trocio, et al. · Journal of Medical Economics · 27
PDF
Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States
2018 · Christine L. Baker, Amol D. Dhamane, et al. · Advances in Therapy · 24
PDF
Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation
2017 · Steven Deitelzweig, Xuemei Luo, et al. · Journal of Managed Care & Specialty Pharmacy · 20
PDF
Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase
2017 · Elias J. Jabbour, Jay Lin, et al. · Journal of Medical Economics · 16
PDF
Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US
2019 · Alpesh Amin, Steven Deitelzweig, et al. · Journal of Medical Economics · 15
PDF
Venous Thromboembolism Prophylaxis and Risk in the Inpatient and Outpatient Continuum of Care Among Hospitalized Acutely Ill Patients in the US: A Retrospective Analysis
2018 · Alpesh Amin, W. Richey Neuman, et al. · Advances in Therapy · 11
Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model
2018 · Elias J. Jabbour, Lisa R. Siegartel, et al. · Journal of Medical Economics · 10
PDF
All-Cause, Stroke/Systemic Embolism–, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants
2018 · Steve Deitelzweig, Xuemei Luo, et al. · Clinical and Applied Thrombosis/Hemostasis · 8
Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States
2017 · Jay Lin, Lisa R. Siegartel, et al. · Clinical Therapeutics · 8
Venous Thromboembolism Prophylaxis and Risk for Acutely Medically Ill Patients Stratified by Different Ages and Renal Disease Status
2019 · Alpesh Amin, W. Richey Neuman, et al. · Clinical and Applied Thrombosis/Hemostasis · 7
PDF
Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States
2017 · Steven B. Deitelzweig, Michael Evans, et al. · Clinical and Applied Thrombosis/Hemostasis · 7
PDF
The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans
2018 · Steven R. Feldman, Jashin J. Wu, et al. · Journal of Medical Economics · 5
PDF
Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States
2018 · Steven Deitelzweig, Jennifer D. Guo, et al. · Clinical and Applied Thrombosis/Hemostasis · 4
42 Incremental Economic Burden Associated With Major Bleeding among Atrial Fibrillation Patients Treated With Factor Xa Inhibitors
2016 · S. Deitelzweig, W.R. Neuman, et al. · Annals of Emergency Medicine · 3
PDF
Correction to: Steven Deitelzweig et al., Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients
2017 · Steve Deitelzweig, Xuemei Luo, et al. · Current Medical Research and Opinion · 2
PDF
Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States
2018 · Elias J. Jabbour, Lisa R. Siegartel, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
A Cost-Effectiveness Analysis of Commonly Used Biologic Drugs for the Treatment of Moderate-To-Severe Psoriasis in the United States
2018 · JJ Wu, SR Feldman, et al. · Value in Health · 1
Systematic Review of Poly (ADP-RIBOSE) Polymerase Inhibitors for Treatment of Ovarian Cancer
2018 · B Menges, C Deitelzweig, et al. · Value in Health · 1
Real World Evaluation of Major Bleeding Risk and Costs for All Causes and Bleeding-related Health Services Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban or Warfarin
2017 · Steven Deitelzweig, Xuemei Luo, et al. · Journal of the American College of Cardiology · 1
PDF
Abstract 17298: Real-world Evaluation of Healthcare Resource Use and Costs of Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Apixaban vs. Warfarin in the US
2016 · Steve Deitelzweig, Xuemei Luo, et al. · Circulation · 1
Works count: 54
Citation count: 368
H-index: 11
I10-index: 12
Year
Topic
Type